Inovio Pharmaceuticals Inc Asset Resilience Ratio
Inovio Pharmaceuticals Inc asset resilience ratio. Inovio Pharmaceuticals Inc (INO) has an Asset Resilience Ratio of 20.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Inovio Pharmaceuticals Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Inovio Pharmaceuticals Inc (2000–2024)
Asset resilience ratio of Inovio Pharmaceuticals Inc from 2000 to 2024. This chart shows how Inovio Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Inovio Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Inovio Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Inovio Pharmaceuticals Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.24 Million | 20.52% |
| Total Liquid Assets | $14.24 Million | 20.52% |
Asset Resilience Insights
- Good Liquidity Position: Inovio Pharmaceuticals Inc maintains a healthy 20.52% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Inovio Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Inovio Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Inovio Pharmaceuticals Inc Asset Resilience Ratio by Year (2000–2024)
Inovio Pharmaceuticals Inc asset resilience ratio by year from 2000 to 2024. The table below shows the annual Asset Resilience Ratio data for Inovio Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 25.00% | $28.30 Million | $113.20 Million | -51.62pp |
| 2023-12-31 | 76.62% | $130.98 Million | $170.95 Million | +17.32pp |
| 2022-12-31 | 59.30% | $206.67 Million | $348.53 Million | -7.28pp |
| 2021-12-31 | 66.57% | $330.17 Million | $495.94 Million | +36.76pp |
| 2020-12-31 | 29.81% | $160.91 Million | $539.77 Million | -16.97pp |
| 2019-12-31 | 46.78% | $67.34 Million | $143.95 Million | +2.89pp |
| 2018-12-31 | 43.88% | $57.54 Million | $131.11 Million | -11.47pp |
| 2017-12-31 | 55.35% | $103.64 Million | $187.24 Million | +6.06pp |
| 2016-12-31 | 49.30% | $85.63 Million | $173.71 Million | +0.03pp |
| 2015-12-31 | 49.27% | $105.36 Million | $213.84 Million | +8.99pp |
| 2014-12-31 | 40.27% | $53.08 Million | $131.79 Million | +18.86pp |
| 2013-12-31 | 21.41% | $18.91 Million | $88.29 Million | +3.62pp |
| 2012-12-31 | 17.80% | $8.03 Million | $45.14 Million | -3.25pp |
| 2011-12-31 | 21.05% | $12.86 Million | $61.11 Million | +17.76pp |
| 2010-12-31 | 3.29% | $1.85 Million | $56.07 Million | -13.50pp |
| 2009-12-31 | 16.80% | $13.54 Million | $80.63 Million | -25.94pp |
| 2007-12-31 | 42.74% | $17.00 Million | $39.78 Million | +1.85pp |
| 2006-12-31 | 40.89% | $14.70 Million | $35.95 Million | -1.42pp |
| 2001-12-31 | 42.31% | $2.81 Million | $6.63 Million | +17.87pp |
| 2000-12-31 | 24.43% | $2.81 Million | $11.49 Million | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more